RMTI Rockwell Medical, Inc. - Common Stock
$7,37
Prix · Aoû 18, 2026
Données fondamentales au Aoû 13, 2026
Fourchette 52 semaines
$1–$8
92% of range
Note des analystes
BUY
8 analysts
Objectif de cours
$30
+307% upside
P/E (TTM)
-4.9
ROE
-15.8%
Marge nette
-7.7%
À propos de Rockwell Medical, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Lire la suite
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
The company's primary customers are dialysis providers.
Products
Triferic
Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transports it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market. In February 2014, the Company completed its long-term safety study for Triferic.
Rockwell Medical began commercializing Triferic (dialysate) and Triferic AVNU (intravenous) in the United States in the second half of 2019 and in early 2021, respectively. Triferic was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire Triferic despite Rockwell's significant effort to partner the program, Rockwell Medical discontinued its New Drug Applications (“NDAs”) for Triferic and Triferic AVNU in the United States in the fourth quarter of 2022.
Calcitriol
Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.
Hemodialysis Concentrates
Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient's bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.
Iron (III) pyrophosphate
One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.
International Partnerships
While Rockwell has discontinued commercialization of Triferic in the United States, the company has established international partnerships with companies seeking to develop and commercialize Triferic outside the United States and is working closely with these international partners to develop and commercialize Triferic in their respective regions.
South Korea for example; Triferic and Triferic AVNU have been approved in South Korea, and our partner, Jeil Pharmaceutical, launched Triferic in South Korea during the third quarter of 2022.
Also, in April 2023, Drogsan submitted a Marketing Authorization application and GMP application for Triferic AVNU to the Turkish Medicines and Medical Devices Agency ("TMMDA"), for which Drogsan received priority status and high priority status, respectively. Taking into consideration that Drogsan was granted an accelerated review for Triferic AVNU with the Turkish regulatory authority, Rockwell anticipates approval for Triferic AVNU in Turkey in 2024. Drogsan is responsible for all regulatory approval and commercialization activities.
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
RMTI Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$7.37
Capitalisation Boursière
$29M
P/E (TTM)
-4.9
BPA (TTM)
$-0.15
Revenus (TTM)
$69M
Rendement div.
—
ROE
-15.8%
Dette/Capitaux propres
0.2
Fourchette 52 semaines
$1 – $8
RMTI Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$69M
2016-12-31
→
2025-12-31
BPA
$-0.15
2016-12-31
→
2025-12-31
Flux de trésorerie libre
$-1M
2024-12-31
→
2025-12-31
Marges
-7.7%
2016-12-31
→
2025-12-31
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
RMTI
Médiane des pairs
P/E (TTM)
-4.9
15.4
P/S (TTM)
0.4
2.8
P/B
0.8
1.6
EV / EBITDA
-10.9
—
Price / FCF (Cours / FCF)
-24.2
—
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
RMTI
Médiane des pairs
Gross Margin (Marge Brute)
16.9%
31.6%
Operating Margin (Marge d'exploitation)
-6.8%
—
Net Profit Margin (Marge nette)
-7.7%
-49.3%
ROA
-9.1%
-54.9%
ROE
-15.8%
-98.0%
ROIC
-10.2%
—
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
RMTI
Médiane des pairs
Debt / Equity (Dette / Capitaux propres)
0.2
0.0
Current Ratio (Ratio de liquidité)
4.0
4.7
Quick Ratio (Ratio de liquidité réduite)
2.0
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
RMTI
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
-31.8%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
-1.7%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
2.2%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
RMTI
Médiane des pairs
RMTI Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
8 analystes
- Achat fort 2 25,0%
- Achat 5 62,5%
- Conserver 1 12,5%
- Vente 0 0,0%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
2 analystes · 2026-08-15
Médiane
$30.00
← En dessous de tous les objectifs
$7.37
Bas
$20.00
Haut
$40.00
Objectif médian
$30.00
+307,3%
Objectif moyen
$30.00
+307,3%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
-0.09%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 30 juin 2026 | $-0.34 | $-0.24 | -0.10% |
| 31 mars 2026 | $-0.40 | $-0.26 | -0.14% |
| 31 décembre 2025 | $-0.10 | $0.20 | -0.30% |
| 30 septembre 2025 | $-0.50 | $-0.46 | -0.04% |
| 30 juin 2025 | $-0.50 | $-0.51 | 0.01% |
| 31 mars 2025 | $-0.04 | $-0.05 | 0.01% |
| 31 décembre 2024 | $-0.02 | $0.02 | -0.04% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| RMTI | $33M | -5.5 | -31.8% | -7.7% | -15.8% | 16.9% |
| UTMD | $178M | 16.1 | -5.8% | 29.3% | 9.5% | 57.1% |
| NSPR | $77M | -2.3 | 28.1% | -543.3% | -129.3% | 29.5% |
| TELA | $53M | -1.4 | 15.8% | -48.4% | -501.1% | 67.7% |
| ADVB | $15M | -4.4 | — | — | -159.1% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 17
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Cost of Revenue | $58M | $84M | $75M | $69M | $64M | $59M | $58M | $65M | $54M | $47M | $46M | $46M | |
| Gross Profit | $12M | $17M | $9M | $4M | $-2M | $3M | $3M | $-2M | $4M | $7M | $9M | $9M | |
| R&D Expense | $0 | $19.0K | $1M | · | · | · | · | $6M | $6M | $6M | $5M | $8M | |
| SG&A Expense | $14M | $14M | $12M | $16M | $15M | $16M | $21M | $22M | $23M | $21M | $19M | $18M | |
| Operating Income | $-5M | $608.0K | $-7M | $-17M | $-30M | $-28M | $-35M | $-32M | $-26M | $-20M | $-15M | $-18M | |
| Interest Expense | · | · | $2M | $2M | $2M | $2M | $25.0K | · | · | · | · | · | |
| Interest Income | · | · | $211.0K | $33.0K | $22.0K | $238.0K | $392.0K | · | · | · | · | · | |
| Other Non-op | $-623.0K | $-1M | $-2M | $-2M | $-2M | $-2M | $397.0K | $313.3K | $1.6K | · | · | · | |
| Pretax Income | $-5M | $-480.0K | $-8M | · | · | · | · | · | $-26M | $-19M | $-14M | $-21M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $404.5K | $0 | $0 | |
| Net Income | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| EPS (Basic) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| EPS (Diluted) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| Shares (Basic) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| Shares (Diluted) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| EBITDA | $-2M | $3M | $-5M | $-16M | $-30M | $-28M | $-34M | $-32M | $-25M | $-19M | $-14M | $-17M |
Bilan 29
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $16M | $9M | $10M | $13M | $49M | $12M | $23M | $8M | $17M | $31M | $66M | |
| Short-term Investments | · | · | · | · | · | · | · | $11M | $25M | $41M | $39M | $20M | |
| Receivables | $8M | $8M | $11M | $6M | $6M | $4M | $4M | $7M | $6M | $6M | $5M | $4M | |
| Inventory | $3M | $6M | $6M | $6M | $4M | $4M | $4M | $4M | $8M | $12M | $8M | $4M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $3M | $3M | $3M | $2M | $2M | · | · | · | |
| Other Current Assets | · | · | · | · | · | · | · | · | $2M | $2M | $1M | $587.2K | |
| Current Assets | $38M | $37M | $29M | $35M | $35M | $69M | $37M | $47M | $49M | $79M | $85M | $95M | |
| PP&E (Net) | $5M | $6M | $6M | $2M | $2M | $3M | $2M | $3M | $3M | $1M | $2M | $1M | |
| PP&E (Gross) | $15M | $16M | $15M | $10M | $10M | $9M | $8M | $9M | $12M | $11M | $11M | $10M | |
| Accum. Depreciation | $11M | $10M | $9M | $8M | $7M | $7M | $6M | $6M | $9M | $10M | $9M | $9M | |
| Goodwill | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $920.7K | $920.7K | $920.7K | $920.7K | $920.7K | |
| Intangibles | $10M | $10M | $11M | $0 | · | · | · | · | $4.0K | $4.4K | $165.7K | $332.7K | |
| Other Non-current Assets | $556.0K | $528.0K | $527.0K | $523.0K | $619.0K | $629.0K | $435.0K | $536.5K | $494.8K | $501.2K | $462.8K | $542.2K | |
| Total Assets | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Accounts Payable | $2M | $3M | $5M | $4M | $4M | $4M | $3M | $4M | $4M | $6M | $4M | $5M | |
| Accrued Liabilities | $4M | $6M | $7M | $8M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | |
| Current Liabilities | $10M | $14M | $17M | $18M | $21M | $13M | $12M | $13M | $9M | $10M | $8M | $10M | |
| Capital Leases | $1M | $2M | $1M | $3M | · | $2M | $2M | · | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $14.0K | $14.0K | $14.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $20M | $27M | $31M | $33M | $46M | $44M | $24M | $25M | $26M | · | · | · | |
| Long-term Debt | $9M | · | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Total Debt | $9M | $8M | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | $268M | $258M | $249M | |
| Paid-in Capital | $440M | $430M | $418M | $403M | $373M | $372M | $327M | $300M | · | · | · | · | |
| Retained Earnings | $-403M | $-398M | $-397M | $-389M | $-370M | $-337M | $-307M | $-272M | $-240M | $-214M | $-195M | $-180M | |
| AOCI | $131.0K | $54.0K | $-1.0K | $163.0K | $52.0K | $57.0K | $52.0K | $63.1K | $-35.4K | $-902.5K | $-915.5K | $-197.7K | |
| Stockholders' Equity | $37M | $33M | $21M | $14M | $3M | $34M | $20M | $27M | $33M | $53M | $62M | $69M | |
| Liabilities + Equity | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Shares Outstanding | 3,940,530 | 3,405,692 | 29,130,607 | 12,163,673 | 8,544,225 | 8,506,651 | 65,378,890 | 57,034,154 | 51,768,424 | 51,527,711 | 51,501,877 | 50,284,007 |
Flux de trésorerie 16
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $1M | $576.0K | $668.0K | $834.0K | $788.0K | $650.1K | $514.4K | $762.4K | $822.3K | $996.3K | |
| Stock-based Comp | $2M | $1M | $932.0K | $315.0K | $943.0K | $475.0K | $5M | $4M | $7M | $10M | $9M | $10M | |
| Amort. of Intangibles | · | · | $300.0K | · | · | · | · | · | · | · | · | · | |
| Restructuring | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-966.0K | $-317.0K | $-11M | $-2M | $-7M | $-3M | $-887.5K | $3M | $-6M | $-8M | $-20M | $27M | |
| Operating Cash Flow | $-659.0K | $4M | $-9M | $-17M | $-34M | $-30M | $-27M | $-20M | $-21M | $-12M | $-13M | $4M | |
| CapEx | $542.0K | $1M | $284.0K | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $-9M | $-5M | $-3M | $-2M | $311.0K | $3M | $-5M | $13M | $15M | $-2M | $-21M | $-9M | |
| Debt Issued | · | · | · | · | $0 | $22M | $0 | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | $0 | $22M | · | · | · | · | · | · | |
| Stock Issued | $8M | $10M | $15M | $15M | · | · | $5M | $22M | $123.6K | · | · | · | |
| Net Stock Activity | $8M | $10M | $15M | · | · | · | · | $22M | · | · | · | · | |
| Financing Cash Flow | $4M | $7M | $11M | $16M | $-2M | $63M | $21M | $22M | $-2M | $80.2K | $-132.7K | $58M | |
| Net Change in Cash | $-5M | $7M | $-1M | $-3M | $-35M | $37M | $-11M | $14M | $-9M | $-14M | $-35M | $54M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | $404.5K | · | · | |
| Free Cash Flow | $-1M | $3M | · | · | · | · | · | · | · | · | · | · |
Rentabilité 8
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% | 4.4% | 4.6% | -2.5% | 6.5% | 12.7% | 16.2% | 15.8% | |
| Operating Margin | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% | -45.7% | -56.3% | -51.2% | -45.2% | -37.9% | -27.3% | -32.4% | |
| Net Margin | -7.7% | -0.47% | -10.1% | -25.7% | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% | -26.1% | -39.4% | |
| Pretax Margin | -7.7% | -0.47% | · | · | · | · | · | · | -45.2% | -36.4% | -26.1% | -39.4% | |
| EBITDA Margin | -3.6% | 2.8% | -6.2% | -22.3% | -47.9% | -44.4% | -55.0% | -50.1% | -44.3% | -36.5% | -25.8% | -30.6% | |
| ROA | -9.1% | -0.86% | -17.1% | -39.2% | -51.7% | -50.6% | -70.5% | -57.7% | -36.5% | -23.2% | -15.5% | -31.8% | |
| ROE | -15.8% | -1.6% | -39.4% | -123.5% | -479.5% | -81.0% | -155.1% | -160.8% | -60.4% | -34.4% | -22.0% | -61.6% | |
| ROIC | -10.2% | 1.5% | · | · | · | · | · | · | -78.8% | -39.0% | -24.2% | -25.6% |
Liquidité et Solvabilité 5
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 | 5.4 | 3.0 | 3.5 | 5.3 | 7.7 | 10.5 | 9.7 | |
| Quick Ratio | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 | 4.1 | 1.3 | 3.1 | 4.3 | 6.3 | 9.4 | 9.2 | |
| Debt / Equity | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 | 0.6 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.2 | 0.3 | 0.4 | 0.5 | 5.2 | 0.6 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -2.9 | -8.7 | -12.9 | -15.1 | · | · | · | · | · | · |
Efficacité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.2 | 1.8 | 1.7 | 1.5 | 1.0 | 1.0 | 1.3 | 1.1 | 0.8 | 0.6 | 0.6 | 0.8 | |
| Inventory Turnover | 12.5 | 14.4 | 12.8 | 13.9 | 16.1 | 15.7 | 15.2 | 11.1 | 5.4 | 4.7 | 7.9 | 13.6 | |
| Receivables Turnover | 8.4 | 10.6 | 9.7 | 12.0 | 12.3 | 14.9 | 11.0 | 9.5 | 9.0 | 9.3 | 11.6 | 12.0 |
Taux de croissance 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -31.8% | 21.4% | 14.8% | 17.6% | -0.43% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -1.7% | 17.9% | 10.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.2% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Net Income TTM | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| Market Cap | $33M | $69M | $55M | $12M | $424M | $1.04B | $1.75B | $1.42B | $3.31B | $3.71B | $5.80B | $5.69B | |
| Enterprise Value | $31M | $62M | $54M | $11M | $431M | $1.01B | · | · | · | · | · | · | |
| P/E | -5.5 | -68.0 | -5.1 | -0.8 | -1.2 | -27.1 | -58.3 | -54.0 | -125.5 | -184.7 | -388.4 | -217.5 | |
| P/S | 0.5 | 0.7 | 0.7 | 0.2 | 6.8 | 16.7 | 28.6 | 22.4 | 57.8 | 69.7 | 104.8 | 104.9 | |
| P/B | 0.9 | 2.1 | 2.6 | 0.9 | 167.2 | 30.4 | 86.4 | 52.0 | 100.7 | 70.1 | 93.1 | 82.8 | |
| P / Tangible Book | 1.2 | 3.2 | 5.7 | 0.9 | 262.6 | 31.3 | · | · | · | · | · | · | |
| P / Cash Flow | -49.6 | 16.5 | -5.8 | -0.7 | -12.6 | -35.1 | -64.3 | -69.4 | -157.0 | -298.1 | -357.2 | 1335.5 | |
| P / FCF | -27.2 | 21.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -12.3 | 22.3 | -10.4 | -0.7 | -14.5 | -36.7 | · | · | · | · | · | · | |
| EV / FCF | -25.7 | 19.5 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.4 | 0.6 | 0.7 | 0.2 | 7.0 | 16.3 | · | · | · | · | · | · | |
| Earnings Yield | -18.1% | -1.5% | -19.6% | -129.7% | -84.9% | -3.7% | -1.7% | -1.8% | -0.80% | -0.54% | -0.26% | -0.46% |
Compte de résultat 14
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18M | $17M | $18M | $16M | $16M | $19M | $25M | $28M | $26M | $23M | $22M | $24M | $18M | $20M | $19M | $19M | |
| Cost of Revenue | $15M | $14M | $14M | $14M | $14M | $16M | $21M | $22M | $21M | $20M | $19M | $22M | $17M | $17M | $17M | $18M | |
| Gross Profit | $3M | $3M | $4M | $2M | $3M | $3M | $4M | $6M | $5M | $3M | $3M | $2M | $1M | $3M | $2M | $777.0K | |
| R&D Expense | $40.0K | · | $0 | $0 | $0 | $0 | $1.0K | $0 | $0 | $18.0K | $168.0K | $494.0K | $167.0K | $278.0K | · | $469.0K | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Operating Income | $-1M | $-1M | $-398.0K | $-2M | $-1M | $-1M | $-519.0K | $2M | $515.0K | $-1M | $-547.0K | $-2M | $-3M | $-1M | $-2M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $431.0K | · | $411.0K | $395.0K | $387.0K | $435.0K | $476.0K | |
| Other Non-op | $-111.0K | $-125.0K | $-156.0K | $-169.0K | $-143.0K | $-155.0K | $-237.0K | $-272.0K | $-172.0K | $-407.0K | $-965.0K | $-135.0K | $-346.0K | $-323.0K | $-396.0K | $-482.0K | |
| Net Income | $-1M | $-2M | $-554.0K | $-2M | $-1M | $-2M | $-756.0K | $2M | $343.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $-2M | $-4M | |
| EPS (Basic) | $-0.34 | $-0.04 | $-0.01 | $-0.05 | $-0.48 | $-0.04 | $-0.03 | $0.05 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| EPS (Diluted) | $-0.70 | $-0.04 | $-0.01 | $-0.05 | $-0.05 | $-0.04 | $-0.02 | $0.04 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| Shares (Basic) | 3,958,568 | 39,418,302 | -68,469,655 | 36,024,940 | 3,431,130 | 34,107,640 | -60,272,092 | 31,551,805 | 30,451,622 | 29,327,204 | -41,054,753 | 27,521,088 | 18,496,640 | 18,359,940 | -24,295,154 | 18,463,673 | |
| Shares (Diluted) | 3,958,568 | 39,418,302 | -68,469,655 | 36,024,940 | 3,431,130 | 34,107,640 | -62,722,609 | 32,420,168 | 32,033,776 | 29,327,204 | -41,054,753 | 27,521,088 | 18,496,640 | 18,359,940 | -24,295,154 | 18,463,673 | |
| EBITDA | $-1M | $-969.0K | · | $-2M | $-1M | $-821.0K | · | $2M | $515.0K | $-779.0K | · | $-2M | $-3M | $-1M | · | $-4M |
Bilan 26
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $10M | $11M | $14M | $12M | $11M | $16M | $12M | $12M | $7M | $9M | $8M | $9M | $11M | $10M | $13M | |
| Receivables | $8M | $9M | $8M | $8M | $8M | $10M | $8M | $9M | $11M | $11M | $11M | $9M | $5M | $6M | $6M | $7M | |
| Inventory | $3M | $3M | $3M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $5M | |
| Prepaid Expense | $441.0K | $1M | $2M | $2M | $943.0K | $988.0K | $1M | $1M | $1M | $910.0K | $1M | $2M | $1M | $1M | $2M | $2M | |
| Current Assets | $36M | $37M | $38M | $38M | $32M | $33M | $37M | $34M | $30M | $27M | $29M | $28M | $28M | $30M | $35M | $42M | |
| PP&E (Net) | $5M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $7M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $14M | $14M | $15M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $15M | $15M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $9M | $10M | $11M | $12M | $11M | $11M | $10M | $10M | $10M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | |
| Goodwill | $920.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | |
| Intangibles | $9M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $11M | $11M | $11M | · | · | $0 | · | |
| Other Non-current Assets | $556.0K | $556.0K | $556.0K | $561.0K | $561.0K | $521.0K | $528.0K | $548.0K | $548.0K | $527.0K | $527.0K | $527.0K | $527.0K | $522.0K | $523.0K | $522.0K | |
| Total Assets | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $5M | $5M | $4M | $6M | $5M | $4M | $3M | |
| Accrued Liabilities | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $5M | $7M | $7M | $4M | $4M | $8M | $6M | |
| Current Liabilities | $11M | $10M | $10M | $10M | $11M | $11M | $14M | $14M | $15M | $15M | $17M | $21M | $17M | $15M | $18M | $19M | |
| Capital Leases | $3M | $3M | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $1M | $2M | $2M | $2M | $3M | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Total Liabilities | $21M | $22M | $20M | $20M | $22M | $22M | $27M | $28M | $30M | $30M | $31M | $31M | $29M | $28M | $33M | $38M | |
| Long-term Debt | $9M | $9M | · | · | · | · | · | · | · | · | · | $9M | $9M | $9M | $9M | $14M | |
| Total Debt | $9M | $9M | · | $9M | $9M | $9M | · | $8M | $8M | $8M | · | $9M | $9M | $9M | · | $14M | |
| Paid-in Capital | $441M | $440M | $440M | $439M | $431M | $431M | $430M | $426M | $422M | $420M | $418M | $417M | $403M | $403M | $403M | $402M | |
| Retained Earnings | $-406M | $-405M | $-403M | $-402M | $-401M | $-399M | $-398M | $-397M | $-399M | $-399M | $-397M | $-396M | $-394M | $-391M | $-389M | $-386M | |
| AOCI | $130.0K | $133.0K | $131.0K | $73.0K | $57.0K | $60.0K | $54.0K | $8.0K | $-5.0K | $24.0K | $-1.0K | $68.0K | $137.0K | $156.0K | $163.0K | $54.0K | |
| Stockholders' Equity | $35M | $36M | $37M | $37M | $30M | $32M | $33M | $29M | $23M | $21M | $21M | $22M | $10M | $13M | $14M | $16M | |
| Liabilities + Equity | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Shares Outstanding | 3,972,029 | 39,470,299 | 39,405,302 | 39,405,301 | 34,430,352 | 34,257,903 | 34,056,920 | 32,318,806 | 31,030,218 | 29,556,474 | 29,130,607 | 28,489,663 | 16,795,673 | 12,552,673 | 12,163,673 | 11,152,673 |
Flux de trésorerie 13
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $492.0K | $511.0K | $546.0K | $544.0K | $563.0K | $539.0K | $543.0K | $543.0K | $549.0K | $545.0K | $550.0K | $564.0K | $170.0K | $160.0K | $154.0K | $143.0K | |
| Stock-based Comp | $403.0K | $479.0K | $457.0K | $532.0K | $382.0K | $445.0K | $382.0K | $321.0K | $338.0K | $251.0K | $218.0K | $212.0K | $309.0K | $193.0K | $220.0K | $177.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Restructuring | · | · | $200.0K | $500.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $448.0K | · | · | · | $-3M | · | · | · | $-1M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $2M | $-167.0K | $2M | $-1M | $2M | $-3M | $865.0K | $4M | $1M | $-2M | $-43.0K | $-4M | $-2M | $-4M | $-112.0K | $-1M | |
| CapEx | $617.0K | $425.0K | $86.0K | $229.0K | $164.0K | $63.0K | $395.0K | $191.0K | $286.0K | $139.0K | $43.0K | · | · | · | · | · | |
| Investing Cash Flow | $-487.0K | $-122.0K | $-4M | $-4M | $-103.0K | $-1.0K | $-332.0K | $-6M | $2M | $-139.0K | $2M | $-10M | $-64.0K | $5M | $3M | $-15M | |
| Stock Issued | · | · | $0 | $8M | $0 | $0 | $4M | $4M | $2M | $560.0K | $1M | $14M | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $560.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $-683.0K | $-813.0K | $-1M | $7M | $-650.0K | $-783.0K | $3M | $2M | $2M | $178.0K | $-742.0K | $13M | $-130.0K | $-631.0K | $-6M | $-2M | |
| Net Change in Cash | $910.0K | $-1M | $-3M | $1M | $1M | $-4M | $3M | $475.0K | $5M | $-2M | $1M | $-1M | $-2M | $792.0K | $-3M | $-18M | |
| Free Cash Flow | · | $-592.0K | · | · | · | $-4M | · | · | · | · | · | · | · | · | · | · |
Rentabilité 6
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.2% | 16.7% | · | 14.3% | 15.6% | 16.1% | · | 22.0% | 17.6% | 13.5% | · | 9.3% | 5.7% | 13.2% | · | 4.2% | |
| Operating Margin | -6.0% | -8.5% | · | -10.0% | -8.4% | -7.2% | · | 6.8% | 2.0% | -5.8% | · | -7.3% | -16.4% | -7.3% | · | -19.8% | |
| Net Margin | -6.6% | -9.3% | · | -11.0% | -9.3% | -8.0% | · | 5.9% | 1.3% | -7.6% | · | -7.9% | -18.3% | -8.9% | · | -22.4% | |
| EBITDA Margin | -6.0% | -5.6% | · | -10.0% | -8.4% | -4.3% | · | 6.8% | 2.0% | -3.4% | · | -7.3% | -16.4% | -6.4% | · | -19.8% | |
| ROA | -2.1% | -2.9% | · | -3.1% | -2.8% | -2.9% | · | 3.0% | 0.75% | -3.8% | · | -3.5% | -6.8% | -4.5% | · | -7.4% | |
| ROE | -3.6% | -4.8% | · | -5.3% | -5.5% | -5.8% | · | 6.6% | 2.1% | -10.4% | · | -9.9% | -22.3% | -45.2% | · | -30.8% |
Liquidité et Solvabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.7 | · | 3.9 | 2.9 | 2.9 | · | 2.4 | 2.0 | 1.8 | · | 1.3 | 1.6 | 2.0 | · | 2.2 | |
| Quick Ratio | 1.7 | 1.9 | · | 2.3 | 1.9 | 1.9 | · | 1.5 | 1.5 | 1.2 | · | 0.8 | 0.8 | 1.1 | · | 1.1 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.4 | 1.0 | 0.7 | · | 0.9 | |
| LT Debt / Equity | 0.2 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.2 | 0.5 | 0.5 | · | 0.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -3.1 | · | -4.2 | -7.5 | -3.7 | · | -7.8 |
Efficacité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.4 | · | 0.5 | 0.6 | 0.5 | · | 0.4 | 0.4 | 0.5 | · | 0.3 | |
| Inventory Turnover | 4.2 | 3.6 | · | 2.8 | 2.7 | 2.9 | · | 3.9 | 3.6 | 3.4 | · | 4.1 | 3.1 | 3.1 | · | 4.0 | |
| Receivables Turnover | 2.2 | 1.9 | · | 1.9 | 1.7 | 1.8 | · | 3.1 | 3.2 | 2.6 | · | 2.8 | 2.7 | 3.0 | · | 2.8 |
Valorisation (TTM) 14
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $67M | $68M | · | $79M | $89M | $96M | · | $101M | $90M | $84M | · | $80M | $75M | $73M | · | $69M | |
| Net Income TTM | $-6M | $-6M | · | $-3M | $-1M | $-1M | · | $-2M | $-7M | $-9M | · | $-11M | $-14M | $-18M | · | $-24M | |
| Market Cap | $22M | $35M | · | $47M | $29M | $39M | · | $128M | $55M | $49M | · | $59M | $92M | $23M | · | $15M | |
| Enterprise Value | $20M | $34M | · | $42M | $25M | $36M | · | $124M | $51M | $51M | · | $60M | $92M | $21M | · | $16M | |
| P/E | -30.6 | -4.9 | · | -12.0 | -21.2 | -22.6 | · | -49.6 | -5.9 | -4.0 | · | -3.6 | -5.8 | -1.1 | · | -0.6 | |
| P/S | 0.3 | 0.5 | · | 0.6 | 0.3 | 0.4 | · | 1.3 | 0.6 | 0.6 | · | 0.7 | 1.2 | 0.3 | · | 0.2 | |
| P/B | 0.6 | 1.0 | · | 1.3 | 1.0 | 1.2 | · | 4.4 | 2.3 | 2.4 | · | 2.8 | 9.6 | 1.8 | · | 0.9 | |
| P / Tangible Book | 0.9 | 1.4 | · | 1.8 | 1.5 | 1.9 | · | 7.2 | 4.5 | 5.4 | · | 6.1 | 10.7 | 2.0 | · | 1.0 | |
| P / Cash Flow | · | -210.4 | · | · | · | -11.1 | · | · | · | -20.6 | · | · | · | -5.9 | · | · | |
| P / FCF | · | -59.3 | · | · | · | -10.9 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -19.2 | -35.5 | · | -26.8 | -18.9 | -43.7 | · | 64.2 | 99.1 | -65.1 | · | -34.8 | -31.1 | -16.7 | · | -4.3 | |
| EV / FCF | · | -58.2 | · | · | · | -10.1 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.3 | 0.5 | · | 0.5 | 0.3 | 0.4 | · | 1.2 | 0.6 | 0.6 | · | 0.8 | 1.2 | 0.3 | · | 0.2 | |
| Earnings Yield | -3.3% | -20.2% | · | -8.3% | -4.7% | -4.4% | · | -2.0% | -17.1% | -24.7% | · | -27.9% | -17.2% | -88.4% | · | -181.1% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $69M | $101M | $84M | $73M | $62M |
| Marge Brute % | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% |
| Marge d'exploitation % | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% |
| Résultat net | $-5M | $-480.0K | $-8M | $-19M | $-33M |
| BPA dilué | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dette / Capitaux propres | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 |
| Ratio de liquidité | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 |
| Ratio de liquidité réduite | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-1M | $3M | — | — | — |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 37 déclarants · $2.7M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 9 (-2 vs T. préc.) | 14 (+9 vs T. préc.) | 6 (-2 vs T. préc.) | 9 (0 vs T. préc.) | +1.0M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $986 089 | 1 182 361 | 36,75% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $677 668 | 1 229 888 | 25,26% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $197 999 | 359 672 | 7,38% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $169 240 | 288 030 | 6,31% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $128 196 | 232 660 | 4,78% | Actions |
| Wealthspire Advisors, LLC | $83 587 | 151 838 | 3,12% | Actions |
| JANE STREET GROUP, LLC | $81 822 | 148 633 | 3,05% | Actions |
| BlackRock, Inc. | $79 688 | 144 756 | 2,97% | Actions |
| STATE STREET CORP | $55 548 | 100 904 | 2,07% | Actions |
| NORTHERN TRUST CORP | $50 570 | 91 862 | 1,88% | Actions |
| PANAGORA ASSET MANAGEMENT INC | $38 179 | 69 353 | 1,42% | Actions |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $27 525 | 50 000 | 1,03% | Actions |
| LPL Financial LLC | $22 163 | 40 259 | 0,83% | Actions |
| WealthTrust Axiom LLC | $18 166 | 33 000 | 0,68% | Actions |
| Spartan Wealth Advisory Services LLC | $13 768 | 25 010 | 0,51% | Actions |
| TWO SIGMA SECURITIES, LLC | $13 621 | 24 743 | 0,51% | Actions |
| Tower Research Capital LLC (TRC) | $7 919 | 14 386 | 0,30% | Actions |
| Burford Brothers, Inc. | $7 799 | 14 168 | 0,29% | Actions |
| XTX Topco Ltd | $6 157 | 11 184 | 0,23% | Actions |
| Vanguard Global Advisers, LLC | $5 825 | 10 571 | 0,22% | Actions |
| Savvy Advisors, Inc. | $5 505 | 10 000 | 0,21% | Actions |
| WELLS FARGO & COMPANY/MN | $2 753 | 5 000 | 0,10% | Actions |
| MORGAN STANLEY | $1 091 | 1 982 | 0,04% | Actions |
| SHP Wealth Management | $782 | 1 421 | 0,03% | Actions |
| IFG Advisory, LLC | $369 | 670 | 0,01% | Actions |
| GROUP ONE TRADING LLC | $255 | 463 | 0,01% | Actions |
| JONES FINANCIAL COMPANIES LLLP | $168 | 258 | 0,01% | Actions |
| OSAIC HOLDINGS, INC. | $150 | 274 | 0,01% | Actions |
| COMERICA BANK | $136 | 163 | 0,01% | Actions |
| BARCLAYS PLC | $115 | 209 | 0,00% | Actions |
| UBS Group AG | $110 | 200 | 0,00% | Actions |
| FIFTH THIRD BANCORP | $90 | 163 | 0,00% | Actions |
| GSA CAPITAL PARTNERS LLP | $38 | 69 800 | 0,00% | Actions |
| Farther Finance Advisors, LLC | $21 | 39 | 0,00% | Actions |
| Leo H. Evart, Inc. | $8 | 9 | 0,00% | Actions |
| Richmond Brothers, Inc. | $3 | 6 | 0,00% | Actions |
| FMR LLC | $3 | 6 | 0,00% | Actions |
Initiés de la société 33 initiés · 17 dirigeants · 18 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Mark Strobeck | President and CEO | 1 juillet 2026 A | 62 349 | 0 | 0 | $0 |
| Stuart M Paul | Chief Executive Officer | 4 septembre 2019 F | 330 056 | 0 | 0 | $0 |
| CHIOINI ROBERT L | Chairman, President and CEO | 15 décembre 2017 M | 2 549 907 | 0 | 0 | $0 |
| Jesse Neri | SVP and CFO | 1 juillet 2026 A | 27 239 | 0 | 0 | $0 |
| Russell Skibsted | EVP, Chief Financial Officer and Chief Business Officer | 9 septembre 2022 A | — | 0 | 0 | $0 |
| Angus W. Smith | Chief Financial Officer | 28 novembre 2019 F | 168 486 | 0 | 0 | $0 |
| Thomas E Klema | Vice President, CFO | 15 décembre 2017 M | 671 492 | 0 | 0 | $0 |
| Heather Hunter | Chief Operating Officer | 1 juillet 2026 A | 28 007 | 0 | 1 | $-3 413 |
| Megan C. Timmins | EVP, CLO & Secretary | 1 juillet 2026 A | 31 240 | 0 | 0 | $0 |
| Timothy Chole | SVP, Chief Commercial Officer | 20 mai 2025 A | 131 035 | 0 | 0 | $0 |
| Marc L Hoffman | Chief Medical Officer | 17 mars 2023 A | 25 665 | 0 | 0 | $0 |
| Paul E Mcgarry | SVP, Finance and CAO | 17 mars 2023 A | 28 515 | 0 | 0 | $0 |
| Ajay Gupta | Sr. VP & Chief Scientific Off. | 7 octobre 2019 F | 576 458 | 0 | 0 | $0 |
| David Kull | Principal Accounting Officer | 25 avril 2019 A | 13 270 | 0 | 0 | $0 |
| Raymond Dennis Pratt | Chief Medical Officer | 25 avril 2019 A | 357 970 | 0 | 0 | $0 |
| Annamaria T Kausz | VP of Drug Development | 23 septembre 2011 A | — | 0 | 0 | $0 |
| Richard C Yocum | VP - Clin. Dev. & Med. Affairs | 15 janvier 2010 A | — | 0 | 0 | $0 |
| Joseph H Dawson | Administrateur | 1 juillet 2026 A | 12 133 | 0 | 0 | $0 |
| Joan Lau | Administrateur | 1 juillet 2026 A | 20 944 | 0 | 0 | $0 |
| Robert S Radie | Administrateur | 1 juillet 2026 A | 23 985 | 0 | 0 | $0 |
| Allen Nissenson | Administrateur | 1 juillet 2026 A | 23 892 | 0 | 0 | $0 |
| John G Cooper | Administrateur | 1 juillet 2026 A | 23 670 | 0 | 0 | $0 |
| Andrea Heslin Smiley | Administrateur | 20 mai 2025 A | 142 062 | 0 | 0 | $0 |
| Mark H Ravich | Administrateur | 20 mai 2025 A | 148 831 | 0 | 0 | $0 |
| John Peter Mclaughlin | Administrateur | 29 janvier 2020 A | 35 174 | 0 | 0 | $0 |
| Russell H Ellison | Administrateur | 9 janvier 2020 A | 10 050 | 0 | 0 | $0 |
| Benjamin Wolin | Administrateur | 6 juin 2019 A | 27 710 | 0 | 0 | $0 |
| Robin L Smith | Administrateur | 6 juin 2019 A | 31 366 | 0 | 0 | $0 |
| Lisa N Colleran | Administrateur | 6 juin 2019 A | 18 674 | 0 | 0 | $0 |
| Patrick J Bagley | Administrateur | 19 mars 2018 A | 116 307 | 0 | 0 | $0 |
| Ronald D Boyd | Administrateur | 19 mars 2018 A | 42 678 | 0 | 0 | $0 |
| Kenneth L Holt | Administrateur | 16 mars 2017 S | 12 630 | 0 | 0 | $0 |
| HAGELSTEIN DAVID A | Détenteur de 10% | 28 janvier 2013 J | 1 360 700 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 15 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Richmond Brothers, Inc., RBI Private Investment I, LLC, RBI Private Investment II, LLC, The RBI Opportunities Fund, LLC, The RBI Opportunities Fund II, LLC, RBI PI Manager, LLC, Richmond Brothers 401(k) Profit Sharing Plan, David S. Richmond, Matthew J. Curfman ×18 dépôts | 6 septembre 2023 | — | Dépôt initial | — | SEC |
| Robert L. Chioini ×10 dépôts | 29 décembre 2017 | — | Dépôt initial | — | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, as amended, David A. Hagelstein | 13 août 2013 | — | Dépôt initial | — | SEC |
| Thomas E. Klema ×3 dépôts | 1 juillet 2013 | — | Dépôt initial | — | SEC |
| Thomas E. Klema (2) | 23 mars 2012 | — | Dépôt initial | — | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, David A. Hagelstein | 8 décembre 2011 | — | Dépôt initial | — | SEC |
| David Hagelstein Charitable Remainder Unitrust Agreement, dated November 20, 2003, David A. Hagelstein, individually and the David A. Hagelstein Revocable Living Trust, dated October 27, 1993 ×4 dépôts | 31 mars 2011 | — | Dépôt initial | — | SEC |
| Personne déclarante non divulguée | 13 février 2007 | — | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée | 13 février 2007 | — | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée | 6 février 2006 | — | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée | 27 décembre 2005 | — | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée | 27 décembre 2005 | — | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée | 18 juillet 2005 | — | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée | 22 avril 2005 | — | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée | 23 janvier 2004 | — | Dépôt initial | Investissement passif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 2 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.